PTPRC and laryngotracheoesophageal cleft: To get more specific ABCG2-positive tumor-initiating cells from LC patients, we sorted CD45−/CD326+/CD338+ cells from 10.0 ml of blood cells from LC patients (Fig. 2g); then we injected the cells into the tail vein of Balb/C nu/nu mice for 4 months.